Induced pluripotent stem cell (iPSC) technology is one of the most transformative innovations in cell therapy. It offers unprecedented opportunities to develop autologous and allogeneic cell therapies for diseases such as age-related macular degeneration [1], retinitis pigmentosa [2], Parkinson’s disease [3,4], chronic heart failure [5,6], spinal cord injury [7], and type I diabetes [8]. Additionally, gene-modified allogeneic iPSC-derived immune cell therapy platforms for CAR-T and CAR-NK have been introduced by knocking out T cell receptor (TCR) and human leukocyte antigens (HLA), as well as knocking in cytokine molecules, to improve persistence and antitumor activity [9,10].
No takes yet. Share an insight, caveat, or question.
Krupalnik et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: